Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus report.
A multidisciplinary expert panel, appointed by the High Council for Public Health, evaluated the scientific evidence on which the recommendations for the appropriate use of the pneumococcal vaccine was based and reviewed the studies that became available since previous reports. The conclusions of the working group, presented in this manuscript, resulted in an update of the Belgian recommendations for pneumococcal vaccination.
Peetermans
W E
WE
Department of General Internal Medicine, Infectious Diseases University Hospital Leuven Herestraat 39 3000 Leuven. willy.peetermans@uz.kuleuven.ac.be
Van de Vyver
N
N
Van Laethem
Y
Y
Van Damme
P
P
Thiry
N
N
Trefois
P
P
Geerts
P
P
Schetgen
M
M
Peleman
R
R
Swennen
B
B
Verhaegen
J
J
D000328:Adult; D000368:Aged; D001530:Belgium; D003362:Cost-Benefit Analysis; D006801:Humans; D011008:Pneumococcal Infections / Q000150:complications / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000191:economics; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines